Across TCGA pan-cancer cohorts, STK39 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK39 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher STK39 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated STK39 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, LIHC, and CHOL are the cancer types where STK39 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.941	0.430	.008	20	view →
LIHC	OS	Median	II,III,IV	0.209	0.718	<.001	18	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	DFS	Median	All	1.000	0.680	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: STK39 tumor-vs-normal RNA expression · all STK39 data types